(Q36283939)

13 August 2017

1 reference

title

Immune responses to human papillomavirus (English)

1 reference

13 August 2017

1

Margaret Stanley

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

13 August 2017

1 reference

13 August 2017

volume

24 Suppl 1

1 reference

13 August 2017

page(s)

S16-22

1 reference

Decoding the patterns of self and nonself by the innate immune system

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Regulatory cells and infectious agents: detentes cordiale and contraire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Antigen-specific memory B cell development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Immunoelectron microscopical localization of human papillomavirus type 16 L1 and E4 proteins in cervical keratinocytes cultured in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Replication of human papillomaviruses in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Immunological events in regressing genital warts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Natural history of cervicovaginal papillomavirus infection in young women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High‐Risk Area for Cervical Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Incidence of venereal warts in human immunodeficiency virus-infected and uninfected women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Immune surveillance in the skin: mechanisms and clinical consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Links between innate and adaptive immunity via type I interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Type I interferons (alpha/beta) in immunity and autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Identification of human papillomavirus seroconversions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

The serological response to papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Immunological analyses of human papillomavirus capsids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

The Shope papilloma-carcinoma complex of rabbits: a model system of neoplastic progression and spontaneous regression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.09.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.09.002

1 reference

13 August 2017

1 reference